
---
title: '宾大团队开发_好操作用得起_的免疫疗法，体内直接生成CAR-T细胞修复受损心脏，扩展平台应用前景'
categories: 
 - 新媒体
 - 果壳网
 - 科学人
headimg: 'https://1-im.guokr.com/DE35iC1kh77JnZbQ6Syl9XYR2JyOP3tFo-di1IMt-vI4BAAAXwUAAEpQ.jpg?imageView2/1/w/555/h/706'
author: 果壳网
comments: false
date: Fri, 07 Jan 2022 06:00:00 GMT
thumbnail: 'https://1-im.guokr.com/DE35iC1kh77JnZbQ6Syl9XYR2JyOP3tFo-di1IMt-vI4BAAAXwUAAEpQ.jpg?imageView2/1/w/555/h/706'
---

<div>   
<section style="line-height: 2;padding-right: 8px;padding-left: 8px;color: rgb(52, 52, 52);box-sizing: border-box;font-size: 16px;"><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;">心脏纤维化（受损心脏组织变硬和形成疤痕）是心脏病的一个标志，并且在心脏疾病恶化为心力衰竭中发挥关键作用。但目前，针对这种心脏纤维化的治疗手段仍然非常有限。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">近期，来自宾夕法尼亚大学的研究者报道了一项新的研究，<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">通过CAR-T修复受损纤维化的心肌细胞，使心脏恢复正常功能</span></strong>。该成果于2022年1月6日发表在《科学》（<em style="box-sizing: border-box;">Science</em>）杂志。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img class="rich_pages wxw-img" data-ratio="1.2731481" data-src="https://1-im.guokr.com/DE35iC1kh77JnZbQ6Syl9XYR2JyOP3tFo-di1IMt-vI4BAAAXwUAAEpQ.jpg" data-type="jpeg" data-w="1080" style="vertical-align: middle;box-sizing: border-box;" src="https://1-im.guokr.com/DE35iC1kh77JnZbQ6Syl9XYR2JyOP3tFo-di1IMt-vI4BAAAXwUAAEpQ.jpg?imageView2/1/w/555/h/706" referrerpolicy="no-referrer"></section></section><section style="font-size: 12px;line-height: 1.4;color: rgb(204, 204, 204);box-sizing: border-box;" powered-by="xiumi.us"><p style="text-align: center;box-sizing: border-box;">该成果于2022年1月6日发表在《科学》杂志 | <em style="box-sizing: border-box;">Science</em></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="margin-top: 10px;margin-bottom: 10px;padding-right: 6px;padding-bottom: 6px;text-align: center;box-sizing: border-box;" powered-by="xiumi.us"><section style="padding-top: 6px;display: inline-block;background-color: rgba(117, 222, 239, 0.45);box-sizing: border-box;"><section style="margin-right: -6px;margin-bottom: -6px;margin-left: 6px;background-color: rgb(12, 31, 56);color: rgb(255, 255, 255);padding-right: 10px;padding-left: 10px;font-size: 18px;letter-spacing: 1px;line-height: 2.5;box-sizing: border-box;"><p style="box-sizing: border-box;">何为CAR-T疗法？</p></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">CAR-T即“嵌合抗原受体T细胞免疫”，是一种细胞免疫治疗方法。这种方法能够<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">利用宿主的T细胞，通过基因编辑技术对其进行改造后，再将其注入患者体内</span></strong>，令其特异性识别并杀死癌细胞。</p><p style="white-space: normal;box-sizing: border-box;"><br></p><p>CAR-T疗法已经在急性白血病、非霍奇金淋巴瘤中取得较好的临床疗效。2021年国内广泛报道的“120万一针治愈癌症”，其背后正是用到CAR-T。目前，已经有不少国家的癌症患者接受了这种疗法。</p><p><br></p><p>因此，人们又开始尝试将CAR-T疗法拓展到新的领域，例如<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">传染病、自身免疫性疾病和心脏病</span></strong>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img class="rich_pages wxw-img" data-ratio="0.312037" data-src="https://2-im.guokr.com/v8Zh4ax08DVzRpyctRmV_UYRbLa2ik6ZTgE4GrCvY444BAAAUQEAAFBO.png" data-type="png" data-w="1080" style="vertical-align: middle;box-sizing: border-box;" src="https://2-im.guokr.com/v8Zh4ax08DVzRpyctRmV_UYRbLa2ik6ZTgE4GrCvY444BAAAUQEAAFBO.png?imageView2/1/w/555/h/173" referrerpolicy="no-referrer"></section></section><section style="font-size: 12px;line-height: 1.4;color: rgb(204, 204, 204);text-align: center;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;">CAR-T疗法的主要步骤 | Wiki</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="margin-top: 10px;margin-bottom: 10px;padding-right: 6px;padding-bottom: 6px;text-align: center;box-sizing: border-box;" powered-by="xiumi.us"><section style="padding-top: 6px;display: inline-block;background-color: rgba(117, 222, 239, 0.45);box-sizing: border-box;"><section style="margin-right: -6px;margin-bottom: -6px;margin-left: 6px;background-color: rgb(12, 31, 56);color: rgb(255, 255, 255);padding-right: 10px;padding-left: 10px;font-size: 18px;letter-spacing: 1px;line-height: 2.5;box-sizing: border-box;"><p style="box-sizing: border-box;">利用CAR-T消除纤维化心肌</p></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">在许多慢性心脏病中，活化的心脏成纤维细胞会不停分泌过量的细胞外基质蛋白，导致心肌纤维化——既使心肌变硬，又对心肌细胞的健康和功能产生负面影响。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">之前的研究表明，使用工程化的CAR-T细胞能够消除活化的心肌成纤维细胞，从而治疗心力衰竭。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">传统方法通过逆转录病毒获得的CAR-T细胞会长期存在患者体内，虽然对于治疗癌症来说有重要意义，但是成纤维细胞的激活不止发生在受损心肌，在其他组织的普通伤口愈合过程中也有，如果使用传统方法就会给患者未来长期的健康带来风险。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">而为了将CAR-T细胞用于心肌纤维化治疗，同时减小安全风险，论文作者Rurik等人开发了一种在体内产生<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">瞬时CAR-T细胞的方法</span></strong><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">，让其仅在短时间发挥作用</span></strong>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img class="rich_pages wxw-img" data-ratio="0.7206054" data-src="https://2-im.guokr.com/ADtZwIlMV7Xo4BCqLV0JhyyYmZjG418zdI9-WA81cwBbAwAAawIAAFBO.png" data-type="png" data-w="859" style="vertical-align: middle;box-sizing: border-box;" src="https://2-im.guokr.com/ADtZwIlMV7Xo4BCqLV0JhyyYmZjG418zdI9-WA81cwBbAwAAawIAAFBO.png?imageView2/1/w/555/h/399" referrerpolicy="no-referrer"></section></section><section style="font-size: 12px;line-height: 1.4;color: rgb(204, 204, 204);box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;text-align: center;">在体内产生瞬时CAR-T细胞可以改善损伤后的心脏功能 | 参考文献[1]</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="margin-top: 10px;margin-bottom: 10px;padding-right: 6px;padding-bottom: 6px;text-align: center;box-sizing: border-box;" powered-by="xiumi.us"><section style="padding-top: 6px;display: inline-block;background-color: rgba(117, 222, 239, 0.45);box-sizing: border-box;"><section style="margin-right: -6px;margin-bottom: -6px;margin-left: 6px;background-color: rgb(12, 31, 56);color: rgb(255, 255, 255);padding-right: 10px;padding-left: 10px;font-size: 18px;letter-spacing: 1px;line-height: 2.5;box-sizing: border-box;"><p style="box-sizing: border-box;">瞬时编辑如何实现？</p></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">研究者们设计了一种针对成纤维细胞激活蛋白(FAP，一种活化成纤维细胞标记物)的CAR的mRNA，并将其包装在靶向T细胞（CD5）的<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">脂质纳米颗粒</span></strong><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">（LNPs）</span></strong>中，再注射到小鼠体内。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">这些纳米颗粒可以在体内传递足够的mRNA，使其在小鼠体内产生具有治疗作用的CAR-T细胞，来消除致病性激活的成纤维细胞，减轻心脏纤维化。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">这些mRNA会被限制在细胞质中，不能进行基因组整合</span></strong>，本质上是不稳定的，并且会在细胞分裂过程中被稀释，因而可以用作短期内的治疗。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">在这项研究中，Rurik等人没有观察到明显的毒性。但他们也注意到，由于一些活化的成纤维细胞不表达FAP，血管周围纤维化在治疗时间之后仍存在。这类成纤维细胞也可能加剧心脏疾病，因此<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">进一步的研究可能会探索更多的治疗靶点</span></strong>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img class="rich_pages wxw-img" data-ratio="0.8467391" data-src="https://1-im.guokr.com/_ywr2OfEFcrpue-1YA27NE9R378RYxjMRYUtnssgAS-YAwAACwMAAFBO.png" data-type="png" data-w="920" style="vertical-align: middle;box-sizing: border-box;" src="https://1-im.guokr.com/_ywr2OfEFcrpue-1YA27NE9R378RYxjMRYUtnssgAS-YAwAACwMAAFBO.png?imageView2/1/w/555/h/469" referrerpolicy="no-referrer"></section></section><section style="font-size: 12px;line-height: 1.4;color: rgb(204, 204, 204);text-align: center;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;">体内生成瞬时工程化T细胞 | 参考文献[2]</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="margin-top: 10px;margin-bottom: 10px;padding-right: 6px;padding-bottom: 6px;text-align: center;box-sizing: border-box;" powered-by="xiumi.us"><section style="padding-top: 6px;display: inline-block;background-color: rgba(117, 222, 239, 0.45);box-sizing: border-box;"><section style="margin-right: -6px;margin-bottom: -6px;margin-left: 6px;background-color: rgb(12, 31, 56);color: rgb(255, 255, 255);padding-right: 10px;padding-left: 10px;font-size: 18px;letter-spacing: 1px;line-height: 2.5;box-sizing: border-box;"><p style="box-sizing: border-box;">优势和前景？</p></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">Rurik等所采用的这种方法，<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">不需要在体外制备CAR-T细胞，省去了许多繁琐的步骤</span></strong>，能够灵活地用抗体修饰LNP以增加靶标特异性，更容易生产出临床级试剂。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">另外，与传统的体外CAR-T细胞制造方法相比，体内CAR-T细胞疗法<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">消除了慢病毒或逆转录病毒基因整合进宿主基因组的风险</span></strong>，以及<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">不必再进行注射前的化疗</span></strong>。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">FAPCAR-T细胞已经在癌症中得到了评估，其他纤维化疾病或相关疾病，如FAP+成纤维细胞的慢性炎症也可能受益于此方法。</p><p style="white-space: normal;box-sizing: border-box;"><br></p><p style="white-space: normal;box-sizing: border-box;">“标准化的 CAR-T 疗法在体外修饰 T 细胞，这种技术不仅昂贵，而且难以扩展使用，”论文的共同作者Drew Qeissman教授说，“在体内生成功能性 CAR-T 细胞，极大地扩展了 mRNA/LNP 平台的应用前景。”</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;">Rurik等研究者的工作为免疫疗法的进一步延伸提供了强有力的理论基础，让复杂又昂贵的个性化免疫疗法，朝着<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">“好操作”又“用得起”</span></strong>的方向迈进了一大步。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="display: flex;align-items: center;box-sizing: border-box;"><section style="flex: 1 1 auto;height: 1px;background-color: rgb(204, 204, 204);box-sizing: border-box;"><section><svg viewBox="0 0 1 1" style="float:left;line-height:0;width:0;vertical-align:top;"/></section></section><section style="flex: 0 1 auto;box-sizing: border-box;"><section opera-tn-ra-cell="_$.pages:0.layers:0.comps:21.col1" style="padding-right: 15px;padding-left: 15px;box-sizing: border-box;"><section style="text-align: center;color: rgb(205, 204, 204);font-size: 14px;line-height: 1.61;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;">参考文献<br style="box-sizing: border-box;"></p></section></section></section><section style="flex: 1 1 auto;height: 1px;transform: matrix(-1, 0, 0, 1, 0, 0);-webkit-transform: matrix(-1, 0, 0, 1, 0, 0);-moz-transform: matrix(-1, 0, 0, 1, 0, 0);-o-transform: matrix(-1, 0, 0, 1, 0, 0);background-color: rgb(204, 204, 204);box-sizing: border-box;"><section><svg viewBox="0 0 1 1" style="float:left;line-height:0;width:0;vertical-align:top;"/></section></section></section></section><section style="line-height: 1.61;color: rgb(205, 204, 204);padding-right: 8px;padding-left: 8px;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;"><span style="font-size: 12px;color: rgb(204, 204, 204);box-sizing: border-box;">[1] Joel G. Rurik et. al., CAR T cells produced in vivo to treat cardiac injury. Science. 375, 91-96(2022)</span></p><p style="box-sizing: border-box;"><span style="font-size: 12px;color: rgb(204, 204, 204);box-sizing: border-box;">[2] Torahito A. Gao1 and Yvonne Y. Chen, T cells to fix a broken heart. Science. 375, 23-24(2022)</span></p><p style="box-sizing: border-box;"><span style="font-size: 12px;color: rgb(204, 204, 204);box-sizing: border-box;">[3] https://www.eurekalert.org/news-releases/939267</span></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="font-size: 12px;color: rgb(120, 120, 120);line-height: 2;letter-spacing: 0px;box-sizing: border-box;" powered-by="xiumi.us"><p style="text-align: center;box-sizing: border-box;"><span style="color: rgb(204, 204, 204);letter-spacing: 0px;box-sizing: border-box;">作者：Seven</span></p><p style="text-align: center;box-sizing: border-box;"><span style="color: rgb(204, 204, 204);box-sizing: border-box;">编辑：酥鱼</span></p><p style="text-align: center;box-sizing: border-box;"><span style="color: rgb(204, 204, 204);box-sizing: border-box;">排版：尹宁流</span></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img class="rich_pages wxw-img" data-ratio="0.452973" data-src="https://2-im.guokr.com/9bCzrk6MBH-ZLw4qBGwui4eFq_ingw6YD-EPsrufn5OdAwAAowEAAEpQ.jpg" data-type="jpeg" data-w="925" style="vertical-align: middle;box-sizing: border-box;" src="https://2-im.guokr.com/9bCzrk6MBH-ZLw4qBGwui4eFq_ingw6YD-EPsrufn5OdAwAAowEAAEpQ.jpg?imageView2/1/w/555/h/251" referrerpolicy="no-referrer"></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="border-bottom: 2px solid rgb(15, 97, 164);text-align: left;font-size: 14px;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;">点击阅读原文即可查看原论文</p></section><section style="margin-left: 8%;margin-right: 8%;line-height: 1.1em;box-sizing: border-box;" powered-by="xiumi.us"><section style="width: 0px;display: inline-block;vertical-align: top;border-top: 1em solid rgb(15, 97, 164);border-left: 0.8em solid transparent !important;border-right: 0.8em solid transparent !important;box-sizing: border-box;"><section><svg viewBox="0 0 1 1" style="float:left;line-height:0;width:0;vertical-align:top;"/></section></section></section></section><p><br></p>
                  
</div>
            